Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Inclusion Criteria:
Exclusion Criteria:
clinicaltrials@claritypharmaceuticals.com+61 (0) 2 9209 4037
Birmingham, Alabama 35249-6830, United States
alstrickland@uabmc.edu205-996-5784
smeady@uabmc.edu205-996-2636
Glenview, Illinois 60026, United States
research@arkansasurology.com5012198900 ext. 9039
research@arkansasurology.com5012198900 ext. 2002
clopez@folioclinicalresearch.com
yzuniga@folioclinicalresearch.com
ucstudy@hs.uci.edu877-827-8839
jjoseph@cira-health.com786-791-1799
amfrazee@iu.edu(317)278-4959
ResearchClinicalTeam@bamfhealth.com
joshua.dejong@corewellhealth.org616-267-7566
rachel.schmidt@corewellhealth.org616-486-1545
tromero@gucancer.com402-991-8468
monali.fatterpekar@mountsinai.org212-241-9955
alex.sents@duke.edu(919) 668-0739
RCRO@UTSouthwestern.edu214-645-1568
Christina.delacruz@panoncologytrials.com787-407-3333
Isamar.alicea@panoncologytrials.com787-407-3333